Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Anxiolytic Drugs: Benzodiazepines and Buspirone

Anxiolytic Drugs: Benzodiazepines and Buspirone

Benzodiazepines are a class of anxiolytic drugs known for their rapid efficacy and high therapeutic-to-lethal dose ratio, but with a potential risk of drug dependence. These drugs are lipophilic, allowing for rapid absorption after oral administration, eventually reaching the central nervous system (CNS). Once in the CNS, benzodiazepines bind to the allosteric site of the GABAA receptor. This binding enhances the inhibitory effects of the neurotransmitter GABA. By doing so, they prevent...

Psychosis: Goals of Pharmacotherapy

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...

Anxiolytic Drugs: Overview

Anxiolytic Drugs: Overview

Anxiolytic drugs are vital in managing anxiety disorders by effectively alleviating symptoms such as excessive fear, tachycardia, and tremors. There are several classes of anxiolytic medications, each with unique mechanisms of action and potential side effects.
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic circuitry.

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

Antiepileptic Drugs: GABAergic Pathway Potentiators

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...

Mania and Antimanic Drugs: Overview

Mania and Antimanic Drugs: Overview

Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The burden of Wilson's disease: Insights into clinical, psychological, and functional dimensions.

Rehabilitacion·2025

Same author

Risk of hepatitis B virus reactivation in patients treated with anti-TNFα agents for immune-mediated inflammatory diseases.

Actas dermo-sifiliograficas·2017

Same author

Distant delivery of a mindfulness-based intervention for people with Parkinson's disease: the study protocol of a randomised pilot trial.

Pilot and feasibility studies·2017

Same author

A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients.

Molecular psychiatry·2016

Same author

A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients.

Molecular psychiatry·2015

Same author

Obesity, but not metabolic syndrome, negatively affects outcome in bipolar disorder.

Acta psychiatrica Scandinavica·2015

Search research articles

Related Experiment Video

Updated: Jul 14, 2026

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

Adjunctive zonisamide for treatment refractory anxiety.

G Kinrys¹, D Vasconcelos e Sa, F Nery

¹Anxiety Disorders Research Program, Cambridge Health Alliance, Cambridge, MA, USA. gkinrys@challiance.org

International Journal of Clinical Practice

|May 17, 2007

Summary

This pilot study suggests zonisamide effectively treats refractory anxiety when added to other medications. Most patients showed significant improvement with mild side effects, warranting further research.

Related Experiment Videos

Last Updated: Jul 14, 2026

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

Area of Science:

Neuroscience
Psychiatry
Pharmacology

Background:

Anxiety disorders are prevalent and often treatment-resistant.
Existing anxiolytic therapies have limitations for severe cases.
Novel therapeutic strategies are needed for refractory anxiety.

Purpose of the Study:

To evaluate the efficacy and tolerability of zonisamide as an adjunctive treatment in patients with treatment-refractory anxiety.
To assess the impact of zonisamide on anxiety symptom severity and overall clinical improvement.

Main Methods:

A pilot, open-label, naturalistic study was conducted on 10 patients with treatment-refractory anxiety.
Adjunctive zonisamide was administered to patients non-responsive to standard anxiolytic therapy.
Primary outcome measures included the Hamilton Anxiety Scale (HAM-A) and Clinical Global Impression (CGI) scales.

Main Results:

Patients experienced significant reductions in HAM-A scores (p < 0.001) and CGI-Severity scores (p < 0.002).
60% of patients met responder criteria (CGI-Improvement ≤ 2).
Zonisamide was generally well-tolerated at a mean dose of 160 mg/day, with mild adverse events.

Conclusions:

Zonisamide shows promise as an effective augmentation strategy for treatment-refractory anxiety.
The anticonvulsant zonisamide may offer a new therapeutic option for severe anxiety.
Larger, controlled trials are necessary to confirm these preliminary findings.